Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02396238 · ClinicalTrials.gov registry record · NA
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
A NA study, sponsored by Cytori Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 88
- Enrollment target
NCT02396238 is a NA study that has completed, run by Cytori Therapeutics. The registered enrollment target is 88 participants.
The verdict
NCT02396238, a NA study, has completed, sponsored by Cytori Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 88 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand dysfunction due to scleroderma.
Interventions
- OTHER Placebo
- DEVICE Celution Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2015-05-15 |
| Est. Completion | 2018-05-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02396238
The ClinicalTrials.gov registry entry for NCT02396238 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytori Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02396238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02396238 about?
NCT02396238 is a clinical study titled "Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)". The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand dysfunction due to scleroderma.
What is the current status of trial NCT02396238?
This trial is currently completed. It is a NA study. The enrollment target is 88 participants. The study started on 2015-05-15. Estimated completion is 2018-05-22.
What interventions are being tested in trial NCT02396238?
The interventions under investigation include: Placebo (OTHER), Celution Device (DEVICE).
Who is sponsoring clinical trial NCT02396238?
This trial is sponsored by Cytori Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.